Țară: Canada
Limbă: engleză
Sursă: Health Canada
PERTUSSIS TOXOID; FILAMENTOUS HAEMAGGLUTININ; PERTACTIN; DIPHTHERIA TOXOID; TETANUS TOXOID; INACTIVATED POLIOVIRUS TYPE I; INACTIVATED POLIOVIRUS TYPE II; INACTIVATED POLIOVIRUS TYPE III
GLAXOSMITHKLINE INC
J07CA02
DIPHTHERIA-PERTUSSIS-POLIOMYELITIS-TETANUS
25MCG; 25MCG; 8MCG; 30UNIT; 40UNIT; 40UNIT; 8UNIT; 32UNIT
SUSPENSION
PERTUSSIS TOXOID 25MCG; FILAMENTOUS HAEMAGGLUTININ 25MCG; PERTACTIN 8MCG; DIPHTHERIA TOXOID 30UNIT; TETANUS TOXOID 40UNIT; INACTIVATED POLIOVIRUS TYPE I 40UNIT; INACTIVATED POLIOVIRUS TYPE II 8UNIT; INACTIVATED POLIOVIRUS TYPE III 32UNIT
INTRAMUSCULAR
100
Schedule D
VACCINES
Active ingredient group (AIG) number: 0839081001; AHFS:
CANCELLED POST MARKET
2021-10-26
_Webtop\1100\607\131-non-pm-Infanrix-IPV.doc _ _August 20, 2014 _ _Page 1 of 16_ PRODUCT MONOGRAPH INFANRIX ® -IPV Combined diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine Sterile suspension for injection Single dose pre-filled syringe Active immunizing agent GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Date of Approval: September 11, 2014 Submission Control No: 177364 _©_ _2014 GlaxoSmithKline Inc. All Rights Reserved _ _®_ _INFANRIX is a registered trade-mark, used under license by GlaxoSmithKline Inc. _ _Webtop\1100\607\131-non-pm-Infanrix-IPV.doc _ _August 20, 2014 _ _Page 2 of 16_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................ 3 SUMMARY PRODUCT INFORMATION ........................................................... 3 DESCRIPTION....................................................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................. 3 CONTRAINDICATIONS ...................................................................................... 4 WARNINGS AND PRECAUTIONS ..................................................................... 4 ADVERSE REACTIONS ....................................................................................... 6 DRUG INTERACTIONS ....................................................................................... 8 DOSAGE AND ADMINISTRATION ................................................................... 9 OVERDOSAGE ................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY ............................................... 10 STORAGE AND STABILITY ............................................................................. 11 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................ 11 PART II: SCIENTIFIC INFORMATION ............................................................ Citiți documentul complet